We demonstrated superior brain delivery via MPC nanoencapsulation, tumor targeting through CXCL13, and complete elimination of brain-metastasized B-cell lymphoma by releasing RTX in the brain. This evidence concerns the gene CXCL13 and B-cell non-Hodgkin lymphoma.